The phase 3 clinical trial of India's first dengue vaccine, DengiAll, began in Rohtak, Haryana. Developed by Panacea Biotec and supported by ICMR, the trial involves 10,335 participants across 19 sites. This marks a significant step in combating dengue, as India currently has no licensed vaccine against the disease.

from Times of India https://ift.tt/Gbs2vVp